Literature DB >> 16158429

Clinical and molecular studies on two further families with Simpson-Golabi-Behmel syndrome.

Germán Rodríguez-Criado1, Luis Magano, Mabel Segovia, Fiorella Gurrieri, Giovanni Neri, Antonio González-Meneses, Ignacio Gómez de Terreros, Rita Valdéz, Ricardo Gracia, Pablo Lapunzina.   

Abstract

The Simpson-Golabi-Behmel syndrome (SGBS) (OMIM 312870) is an overgrowth/multiple congenital anomalies syndrome caused by a semi-dominant X-linked gene encoding glypican 3 (GPC3). It shows great clinical variability, ranging from mild forms in carrier females to lethal forms with failure to thrive in males. The most consistent findings in SGBS are pre- and postnatal macrosomia, characteristic facial anomalies and abnormalities affecting the internal organs, skeleton, and on some occasions, mental retardation of variable degree. SGBS is also associated with an increased risk of developing embryonal tumors, mostly Wilms and liver tumors. We describe two molecularly-confirmed families with SGBS. All patients had typical manifestations of SGBS including some female relatives who had minor manifestations of the disorder. Some patients had novel findings such as a deep V-shaped sella turcica and six lumbar vertebrae. Molecular studies in affected patients showed a deletion of exon 6 in family 1 and an intronic mutation in family 2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16158429     DOI: 10.1002/ajmg.a.30920

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  2 in total

1.  Glypican 3 overexpression in primary and metastatic Wilms tumors.

Authors:  Maria Tretiakova; Debra L Zynger; Chunyan Luan; Nicole K Andeen; Laura S Finn; Masha Kocherginsky; Bin T Teh; Ximing J Yang
Journal:  Virchows Arch       Date:  2014-11-04       Impact factor: 4.064

Review 2.  Simpson-Golabi-Behmel syndrome types I and II.

Authors:  Jair Tenorio; Pedro Arias; Víctor Martínez-Glez; Fernando Santos; Sixto García-Miñaur; Julián Nevado; Pablo Lapunzina
Journal:  Orphanet J Rare Dis       Date:  2014-09-20       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.